Herantis Pharma Plc

Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Diseases

Herantis Pharma releases 2H and FY 2025 report today

Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096

Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease

Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096